What question did this study set out to answer?

July 16, 2003European Journal of Clinical Investigation

Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure

View Full Paper

Ask AI

Bookmark

Why the study?

Are plasma levels of metalloproteinases 2 and 9 increased in patients with heart failure compared to control subjects?

Population

51 patients with heart failure and 52 control subjects

Design

Case-control

Authors

PAPaola AltieriOspedale Policlinico San Martino CBCinzia BrunelliFondazione IRCCS Istituto Nazionale dei Tumori SGSilvano GaribaldiUniversity of Genoa

Discussion

Member takes

Implication

Elevated MMP-2/9 activity was associated with heart failure; leaves open their value as progression markers or therapeutic targets.

Key Points

To determine whether plasma activities and concentrations of metalloproteinase-2, metalloproteinase-9, and their tissue inhibitors (TIMP-1 and TIMP-2) are elevated in patients with heart failure.
Case-control design comparing venous blood samples from 51 patients with heart failure against 52 control subjects.
Plasma samples were evaluated for gelatinolytic enzyme activity using zymography and quantified for total protein levels.
Heart failure patients had significantly higher mean ± SE activity levels (ng/mL) than controls for prometalloproteinase-9 (95.1 ± 11.2 vs 38.9 ± 4.5, P < 0.05), active metalloproteinase-9 (18.4 ± 2.5 vs 10.9 ± 1.3, P < 0.05), and prometalloproteinase-2 (571.4 ± 26.1 vs 456.8 ± 21.1, P < 0.05).
Circulating metalloproteinase tissue inhibitor-1 concentrations were significantly elevated in heart failure patients, whereas tissue inhibitor-2 showed no significant difference between groups.
Metalloproteinase concentrations did not correlate with NYHA clinical class, though prometalloproteinase-2 correlated positively with left ventricular volumes and negatively with lipid levels.

Structured PICO

Are plasma levels of metalloproteinases 2 and 9 increased in patients with heart failure compared to control subjects?

Population

51 patients with heart failure and 52 control subjects

Comparator

52 control subjects

Outcome

Plasma activity levels of metalloproteinase-2, metalloproteinase-9, and their tissue inhibitors (TIMP-1, TIMP-2)surrogate

Elevated circulating levels of metalloproteinases 2 and 9 in heart failure patients suggest persistent extracellular remodeling regardless of clinical phase.

Cite This Study

Altieri et al. (2003) studied this question.

synapsesocial.com/papers/6a7412ce798fc0afde3917ca https://doi.org/10.1046/j.1365-2362.2003.01187.x

View Full Paper

Ask AI

Bookmark

Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider